Table 3.

Multivariable Cox regression analysis for overall survival of AML patients.

Data set/cohort	Variable	4-GES			L-24			M-7			W-3
		HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
GSE12417/1	GE score, high vs. low	3.8	2.3–6.2	8.8 * 10−08	2.25	1.5–3.4	7.5 * 10−05	na	Na	na	1.51	1.07–2.14	0.021
	Age (years)	1.02	1.0–1.0	0.006	1.03	1.0–1.04	0.0003	na	Na	na	1.03	1.01–1.04	0.0004
GSE12417/2	GE score, high vs. low	4.58	1.1–18.9	0.035	ns	ns	ns	2.68	1.5–4.9	0.0016	2.01	1.1–3.7	0.022
	Age (years)	1.04	1.0–1.1	0.008	ns	ns	ns	1.03	1.0–1.06	0.0063	1.03	1.0–1.1	0.0079
GSE6891/1	GE score, high vs. low	1.69	1.2–2.5	0.008	1.1	0.8–1.6	0.56	2.0	1.4–2.8	5.3 * 10−05	ns	ns	ns
	Cytogenetic riska	1.91	1.5–2.5	1.4 * 10−06	1.97	1.5–2.6	3.7 * 10−07	1.98	1.6–2.5	2.9 * 10−08	ns	ns	ns
	CEBPAm (w/m/b)	0.79	0.1–6.4	0.828	0.84	0.1–8.1	0.878	0.95	0.1–6.4	0.957	ns	ns	ns
	CEBPAm (yes/no)	0.94	0.0–57.1	0.976	0.71	0.0–61.2	0.878	0.66	0.01–27.5	0.83	ns	ns	ns
	EVI1 expression (+/−)	0.82	0.5–1.5	0.511	0.95	0.5–1.7	0.854	0.89	0.5–1.6	0.681	ns	ns	ns
	FLT3-ITD	1.38	0.9–2.0	0.106	1.69	1.2–2.5	0.006	1.82	1.3–2.6	0.0008	ns	ns	ns
GSE6891/2	GE score, high vs. low	2.24	1.5–3.4	0.0001	1.33	0.9–2.0	0.173	1.7	1.1–2.5	0.0086	ns	ns	ns
	Age (years)	1.01	1.0–1.03	0.281	1.01	1.0–1.03	0.128	1.01	1.0–1.03	0.102	ns	ns	ns
	Cytogenetic riska	1.13	0.8–1.6	0.528	1.22	0.9–1.75	0.27	1.35	1.0–1.92	0.092	ns	ns	ns
	EVI1 expression (+/−)	3.73	1.8–7.6	0.0002	2.95	1.5–6.0	0.0025	2.9	1.4–5.8	0.0028	ns	ns	ns
GSE37642	GE score, high vs. low	2.13	1.6–2.8	1.8 * 10−07	1.49	1.2–1.9	0.0016	na	Na	na	ns	ns	ns
	Age (years)	1.03	1.0–1.04	5.6 * 10−12	1.03	1.0–1.04	1.5 * 10−13	na	Na	na	ns	ns	ns
	ELN scoreb	1.26	1.1–1.4	7.1 * 10−05	1.33	1.2–1.5	4.1 * 10−07	na	Na	na	ns	ns	ns
	FAB, M1 vs. others	1.06	0.8–1.4	0.718	0.95	0.7–1.3	0.745	na	Na	na	ns	ns	ns
	FAB, M4 vs. others	1.32	1.0–1.8	0.074	1.45	1.1–2.0	0.017	na	Na	na	ns	ns	ns
TCGA_LAML	GE score, high vs. low	1.52	1.0–2.3	0.051	1.3	0.8–2.1	0.249	ns	Ns	ns	2.45	1.4–4.3	0.002
	Age (years)	1.03	1.0–1.1	0.00013	1.03	1.0–1.1	8.8 * 10−05	ns	Ns	ns	1.04	1.0–1.1	2.3 * 10−05
	Cytogenetic riska	1.29	0.9–1.9	0.179	1.25	0.8–1.9	0.265	ns	Ns	ns	1.49	1.0–2.1	0.033

Parameters provided with the respective data sets were first tested in univariable analyses (Supplementary Table S1); those that resulted as significant were included in the multivariable models, whose results are summarized in this table. 4-GES, 4-gene expression score; L-24, 24-gene expression signature by Li et al.¹⁶; M-7, 7-gene expression signature by Marcucci et al.¹⁹; W-3, 3-gene expression signature by Wilop et al.²⁰; HR, hazard ratio; CI, confidence interval; GE score, gene expression score; CEBPAm, CEBPA mutation; w, wild type; m, monoallelic; b, biallelic. ^aAssignment to cytogenetic risk groups were included in the respective GEO entries. ^bAssignment to ELN risk groups was provided by T. Herold, University of Munich, Department of Internal Medicine III, Munich, Germany. No relevant patient data were provided in GSE71014; therefore, multivariable analyses could not be performed. Significant p-values and corresponding HRs and Cis are indicated in bold letters. na, score could not be calculated because 2 signature genes were not represented on HG-U133A microarrays; ns, no statistical significance found in univariable analyses, thus, no multivariable analyses were performed.